1. Pink Sheet
  2. >>Market Access

Senate 340B Draft Bill May Add Contract Pharmacy Limits, Has Placeholder For Patient Definition

 
• By Cathy Kelly

A bipartisan group of senators issues a request for information to fill gaps in their wide-ranging draft bill on the 340B program. The legislation covers the participation of contract pharmacies, eligibility of "child sites," claims transparency, abuses by pharmacy benefit managers, and a third party claims clearinghouse that would monitor for duplicate discounts.

falling pills
The comprehensive bill may not get far in Congress in the near term. • Source: Shutterstock

A new draft bill to reform and update the 340B outpatient drug discount program would codify the participation of contract pharmacies in the program and require manufacturers to provide discounts to those retailers without the conditions or restrictions that many now impose.

But the group of senators authoring the bill also seem open to limits on the number or location of contract pharmacies that participate in the program, which could be good news for manufacturers, but a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.

Will International Prices Influence Medicare Price Negotiation?

 
• By Cathy Kelly

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.

Managed Access Agreement Fails To Help BioMarin’s Brineura Secure Routine Reimbursement In England

 
• By Francesca Bruce

BioMarin’s ultra-rare disease drug Brineura has breached cost-effectiveness thresholds for highly specialized treatments in England and looks set to be denied routine funding on the National Health Service.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.

More from Pink Sheet

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 
• By Neena Brizmohun

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.